EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment

Yuxuan Song, Yun Peng, Caipeng Qin, Yulong Wang, Wenbo Yang, Yiqing Du, Tao Xu iD

Journal for ImmunoTherapy of Cancer · 2023-09 · 11 (9) · e006643

DOI: 10.1136/jitc-2022-006643 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 30.09.2023. Verfasst von Yuxuan Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Receptor, Fibroblast Growth Factor, Type 3, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Science and Technology Commission of China, Beijing Natural science foundation of China, Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint blockade (ICB) therapy holds promise in metastatic urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell-depleted microenvironment in UC, which led to the hypothesis that FGFR3 mutation might attenuate response to ICB in patients with metastatic UC. The study aims to compare prognosis and response between patients with FGFR3-mutated and FGFR3-wildtype metastatic UC after ICB therapy, and decode the potential molecular mechanisms.

Methods

Based on the single-arm, multicenter, phase 2 trial, IMvigor210, we conducted a propensity score matched (PSM) analysis. After a 1:1 ratio PSM method, 39 patients with FGFR3-mutated and 39 FGFR3-wildtype metastatic UC treated with atezolizumab were enrolled. A meta-analysis through systematical database retrieval was conducted for validation. In addition, we performed single-cell RNA sequencing on three FGFR3-mutated and three FGFR3-wildtype UC tumors and analyzed 58,069 single cells.

Results

The PSM analysis indicated FGFR3-mutated patients had worse overall survival (OS) in comparison to FGFR3-wildtype patients (HR=2.11, 95% CI=(1.16 to 3.85), p=0.015) receiving atezolizumab. The median OS was 9.2 months (FGFR3-mutated) versus 21.0 months (FGFR3-wildtype). FGFR3-mutated patients had lower disease control rate than FGFR3-wildtype patients (41.0% vs 66.7%, p=0.023). The meta-analysis involving 938 patients with metastatic UC confirmed FGFR3 mutation was associated with worse OS after ICB (HR=1.28, 95% CI=(1.04 to 1.59), p=0.02). Single-cell RNA transcriptome analysis identified FGFR3-mutated UC carried a stronger immunosuppressive microenvironment compared with FGFR3-wildtype UC. FGFR3-mutated UC exhibited less immune infiltration, and lower T-cell cytotoxicity. Higher TREM2+ macrophage abundance in FGFR3-mutated UC can undermine and suppress the T cells, potentially contributing to the formation of an immunosuppressive microenvironment. Lower inflammatory-cancer-associated fibroblasts in FGFR3-mutated UC recruited less chemokines in antitumor immunity but expressed growth factors to promote FGFR3-mutated malignant cell development. FGFR3-mutated UC carried abundance of malignant cells characterized by high hypoxia/metabolism and low interferon response phenotype.

Conclusions

FGFR3 mutation can attenuate prognosis and response to ICB in patients with metastatic UC. FGFR3-mutated UC carries a stronger immunosuppressive microenvironment in comparison with FGFR3-wildtype UC. Inhibition of FGFR3 might activate the immune microenvironment, and the combination of FGFR inhibitor targeted therapy and ICB might be a promising therapeutic regimen in metastatic UC, providing important implications for UC clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellReceptor, Fibroblast Growth Factor, Type 3Urinary Bladder NeoplasmsHumansImmune Checkpoint InhibitorsImmunosuppressive AgentsMulticenter Studies as TopicMutationTumor Microenvironment

Stichwörter der Autor:innen

Genetic MarkersImmune Checkpoint InhibitorsImmunotherapy

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive AgentsReceptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • Department of Urology, Peking University People's Hospital, Beijing, China.
  • Department of Urology, Peking University People's Hospital, Beijing, China xutao@pkuph.edu.cn duyiqing@bjmu.edu.cn.

ORCID-Profile: Tao Xu

Förderung

  • Beijing Municipal Science and Technology Commission of China
  • Beijing Natural science foundation of China
  • Research and Development Program of China
  • National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research of China

Zitieren

APA

Song, Y., Peng, Y., Qin, C., Wang, Y., Yang, W., Du, Y., & Xu, T. (2023). Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. Journal for ImmunoTherapy of Cancer, 11(9), e006643. https://doi.org/10.1136/jitc-2022-006643

Vancouver

Song Y, Peng Y, Qin C, Wang Y, Yang W, Du Y, et al. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. Journal for ImmunoTherapy of Cancer. 2023;11(9):e006643. doi:10.1136/jitc-2022-006643

BibTeX
@article{Song2023,
  author = {Song, Yuxuan and Peng, Yun and Qin, Caipeng and Wang, Yulong and Yang, Wenbo and Du, Yiqing and Xu, Tao},
  title = {Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {9},
  pages = {e006643},
  doi = {10.1136/jitc-2022-006643}
}
Kostenlos starten →